^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:carfilzomib (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    BeiGene Press Release
    Title:

    BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

    Published date:
    07/09/2021
    Excerpt:
    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration (NMPA) has conditionally approved KYPROLIS® (carfilzomib) for injection in combination with dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma...
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    08/20/2020
    Excerpt:
    Kyprolis is a proteasome inhibitor that is indicated...for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with...Lenalidomide and dexamethasone...Dexamethasone...Daratumumab and dexamethasone.
    Secondary therapy:
    daratumumab + dexamethasone; lenalidomide + dexamethasone; dexamethasone
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Scottish Medicines Consortium
    Title:

    carfilzomib (Kyprolis) is accepted for use within NHS Scotland.

    Published date:
    07/07/2017
    Excerpt:
    Carfilzomib (Kyprolis) is accepted for use within NHS Scotland...In combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    11/19/2015
    Excerpt:
    Kyprolis in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    Kyprolis is a proteasome inhibitor that is indicated:...as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NICE
    Title:

    Carfilzomib for previously treated multiple myeloma

    Published date:
    11/18/2020
    Excerpt:
    Carfilzomib with dexamethasone is recommended as an option for treating multiple myeloma...
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Multiple Myeloma: Therapy for previously treated multiple myeloma…Other Recommended Regimens…Carfilzomib/cyclophosphamide/dexamethasone. Multiple Myeloma: Therapy for previously treated multiple myeloma…Useful In Certain Circumstances… Carfilzomib/cyclophosphamide/thalidomide/dexamethasone. …the NCCN Multiple Myeloma Panel has included the combination of carfilzomib (twice weekly) and dexamethasone as a category 1, preferred option for patients with relapsed/refractory MM. The following regimen has been added to Therapies for Patients with Late Relapses (>3 prior therapies):...Bendamustine/carfilzomib/dexamethasone
    Secondary therapy:
    cyclophosphamide + dexamethasone; cyclophosphamide + dexamethasone + thalidomide; dexamethasone; dexamethasone + bendamustine
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Nature
    Title:

    Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

    Published date:
    10/16/2020
    Excerpt:
    These post hoc exploratory analyses of extended follow-up data from the ASPIRE and ENDEAVOR pivotal phase 3 studies of carfilzomib in RRMM showed that best responses (≥CR) were achieved by 31.8 and 13.0% of patients treated with KRd and Kd, respectively...Best responders presented a longer exposure to carfilzomib and had longer median PFS and OS than patients who achieved VGPR/PR in both studies.
    Secondary therapy:
    dexamethasone
    DOI:
    10.1038/s41375-020-01049-5
    Trial ID:
    ENDEAVOR; ASPIRE
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Amgen Press Release
    Title:

    FDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis (Carfilzomib) in Relapsed Multiple Myeloma

    Published date:
    09/18/2015
    Excerpt:
    Amgen today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental New Drug Application (sNDA) of Kyprolis (carfilzomib) for Injection for patients with relapsed multiple myeloma. The sNDA is designed to expand the current indication to include Kyprolis in combination with dexamethasone for patients who have received at least one prior therapy.
    Secondary therapy:
    dexamethasone